REPL vs ZBH · $825.7M cap vs P/E 23, rev $7.68B
Replimune Group Inc (REPL) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
REPL does not have a complete income-statement cache yet.
Latest reported ZBH revenue for 2024-12-31 was $7.68B. Net income was $905.3M. Revenue was up 3.8% from 2023-12-31 to 2024-12-31. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
REPL currently screens at market cap $825.7M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the REPL and ZBH stock pages for the full models.
Not investment advice.